dr. A.M.E. (Annemiek) Walenkamp

Medical Oncologist (MD)

dr. A.M.E. (Annemiek) Walenkamp
a.walenkamp umcg.nl


  1. 2020
  2. 2019
  3. French, P. J., Eoli, M., Sepulveda, J. M., de Heer, I., Kros, J. M., Walenkamp, A., ... van den Bent, M. (2019). Defining EGFR amplification status for clinical trial inclusion. Neuro-Oncology, 21(10), 1263-1272. https://doi.org/10.1093/neuonc/noz096
  4. Lassman, A. B., Aldape, K. D., Ansell, P. J., Bain, E., Curran, W. J., Eoli, M., ... van den Bent, M. J. (2019). Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. JOURNAL OF NEURO-ONCOLOGY, 144(1), 205-210. https://doi.org/10.1007/s11060-019-03222-y
  5. 2018
  6. Salazar, R., Garcia-Carbonero, R., Libutti, S. K., Hendifar, A. E., Custodio, A., Guimbaud, R., ... Yao, J. C. (2018). Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors. The Oncologist, 23(7), 766-e90. https://doi.org/10.1634/theoncologist.2017-0144
  7. 2017
  8. van Linde, M. E., Brahm, C. G., Hamer, P. C. D. W., Reijneveld, J. C., Bruynzeel, A. M. E., Vandertop, W. P., ... Verheul, H. M. W. (2017). Treatment outcome of patients with recurrent glioblastoma multiforme: A retrospective multicenter analysis. JOURNAL OF NEURO-ONCOLOGY, 135(1), 183-192. https://doi.org/10.1007/s11060-017-2564-z
  9. 2016
  10. Erdem-Eraslan, L., van den Bent, M. J., Hoogstrate, Y., Naz-Khan, H., Stubbs, A., van der Spek, P., ... French, P. J. (2016). Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. Cancer Research, 76(3), 525-534. https://doi.org/10.1158/0008-5472.CAN-15-0776
  11. 2015
Previous 1 2 Next

ID: 393545